ACE-031 vs MGF

Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously

ACE-031 is a soluble decoy receptor fusion protein consisting of the extracellular domain of activin type IIA receptor (ActRIIA) linked to a human IgG1 Fc region, developed by Acceleron Pharma to bind and sequester myostatin, activin, and related TGF-beta superfamily ligands that negatively regulate muscle mass, with the goal of promoting muscle growth in severe wasting conditions including Duchenne muscular dystrophy. By competitively binding circulating myostatin and related ligands, ACE-031 reduces signaling through the Smad2/3 pathway that suppresses muscle satellite cell activation and protein synthesis; in preclinical models of myopathy, blockade of ActRIIA signaling produced significant increases in lean mass, supporting its evaluation in Phase 2 human trials. A Phase 2 randomized placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy demonstrated significant increases in lean body mass; however, the trial was halted early due to vascular-related adverse events including epistaxis and telangiectasias, attributed to off-target inhibition of angiogenic TGF-beta family ligands, and the Acceleron clinical program was subsequently discontinued. ACE-031 has no FDA approval and is not approved for any indication; commercial development was halted due to the adverse event signal identified in the clinical trial; it is not commercially available, and the vascular safety concern inherent to pan-ActRIIA ligand inhibition represents an unresolved risk that precludes its extrapolation to general performance or muscle enhancement applications.

Splice variant of IGF-1; acts locally at site of muscle damage to activate satellite cells (muscle stem cells) for repair and hypertrophy

Mechano growth factor (MGF), also designated IGF-1Ec, is a splice variant of the IGF-1 gene produced locally in skeletal muscle in response to mechanical loading and tissue microdamage, and is proposed to function as an autocrine/paracrine signal that activates muscle satellite cells and initiates the early repair response, a role distinct from the endocrine actions of systemic IGF-1. The unique C-terminal E-peptide domain of MGF is proposed to be the bioactive moiety responsible for satellite cell activation and progenitor cell proliferation, acting through mechanisms that are at least partially independent of IGF-1R and specific to the mechanical stress response rather than systemic growth signaling. Human muscle progenitor cell studies have demonstrated that the MGF E-peptide activates muscle progenitor cells and enhances their fusion potential across different age groups, suggesting a role in the age-related decline in muscle repair capacity. MGF is a research compound with no regulatory approval in any jurisdiction; exogenous administration is investigational, no human clinical pharmacokinetic or safety data has been established, and published evidence is limited to in vitro and preclinical contexts. MGF vs PEG-MGF: native MGF has a very short half-life in circulation, limiting its duration of action after exogenous administration. PEG-MGF (pegylated MGF) is a chemically stabilized version in which polyethylene glycol is conjugated to the peptide to extend its biological half-life — the same technology used to extend the half-life of therapeutic proteins such as PEG-EPO. Research compound suppliers often offer both forms; PEG-MGF is the more commonly studied variant in animal myopathy models for this pharmacokinetic reason. Neither form has human clinical data. MGF in muscle research: interest in MGF as a research compound centers on its proposed role in the lag phase of muscle repair following eccentric exercise-induced damage — the window when satellite cells are activated before proliferating and fusing into existing myofibers. In aged muscle, MGF expression following mechanical loading is reduced relative to young tissue, and this deficit has been proposed as a contributing factor to age-related sarcopenia in the research literature. Providers offering research peptides in the performance and recovery category are listed in the PeptideBase directory.